Credit Suisse starts Akili coverage ewith 'outperform' rating

Akili

24/10/2022 12:44

** Credit Suisse starts coverage on ADHD-focused therapeutic
video-game maker Akili Inc  AKLI.O  with "outperform" rating;
sets PT of $5
    ** Says co has a significant unmet need for EndeavorRx, its
video-game treatment for children with
Attention-Deficit/Hyperactivity Disorder (ADHD), as stigma and
side-effect limit use of medication
    ** EndeavorRx, which has been approved by the U.S. Food and
Drug Administration, can be attractive to healthcare providers,
brokerage says 
    ** EndeavorRx, however, faces constraints in near-term sales
due to lesser product awareness - CS
    ** Brokerage adds that co's data on EndeavorRx requires more
real-world evidence 
    ** AKLI was taken public this year through a deal with one
of Chamath Palihapitiya's blank-check companies  urn:newsml:reuters.com:*:nL1N2ZY1B7
    ** Stock down ~80% since listing, as of last close 
 (Reporting by Anirban Chakroborti in Bengaluru)
 ((Anirban.Chakroborti@thomsonreuters.com;))